RxDoctor Payments Data

Matthew Gornet

Chesterfield, MONPI 1962406207

Payments from drug & device makers

What this record shows

This record is dominated by royalties or licence payments: $213,168 of the $245,671 with a category attached, or 86.8%. Medtronic accounts for 94.0% of it on its own, with 6 other manufacturers making up the rest.

$245,671in general payments, 2019–2025

Across 163 payments — averaging $1507.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$231K
  • Aesculap Implant Systems, LLC$7K
  • Medical Device Business Services, Inc.$6K
  • Surgalign Spine Technologies, Inc.$2K
  • Orthofix Medical, Inc.$21
  • Johnson & Johnson$16
  • plus $12 from 1 others
$566,982in research payments, 2019–2025

Across 51 payments — averaging $11,117 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Orthofix Medical, Inc.$564K
  • Medtronic$3K

What the payments were for

  • Royalty or licence$213,16887%
  • Consulting fees$8,5503%
  • Speaking & faculty fees$21,3759%
  • Travel & lodging$580%
  • Food & beverage$2,3681%
  • Gifts$1530%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cyclobenzaprine Hcl23$179
Tramadol Hcl15$131
Meloxicam39$89
Prednisone11$38

Paid to pharmacies, not to this prescriber.

Where these figures come from

Is this you, or does something look wrong? →